ASH 2025

ASH 2025: New combination approach aims to make CAR T more durable in lymphoma

ASH 2025: Milder chemo works for rare, aggressive lymphoma

ASH 2025: ‘Ready-made’ T-cell gene therapy tackles ‘incurable’ T-cell leukaemia

ASH 2025: New data highlights promise of pivekimab sunirine in two aggressive blood cancers ​

ASH 2025: New combination approach aims to make CAR T more durable in lymphoma

ASH 2025: Adding epcoritamab to standard second-line therapy improves follicular lymphoma outcomes

ASH 2025: Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL

ASH 2025: AI uncovers how DNA architecture failures trigger blood cancer

ASH 2025: Study connects Agent Orange exposure to earlier and more severe cases of myelodysplastic syndrome

ASH 2025: New findings support a chemo-free approach for treating Ph+ ALL

ASH 2025: Study suggests that a virtual programme focusing on diet and exercise can help reduce side effects of lymphoma treatment

ASH 2025: CAR T cell therapy shows promising phase II trial results in multiple myeloma

ASH 2025: Protective regimen allows successful stem cell transplant even without close genetic match between donor and recipient

ASH 2025: Antibody therapy eradicates traces of multiple myeloma in preliminary trial

ASH 2025: Home-based monitoring could transform care for patients receiving T-cell redirecting therapies

ASH 2025: Developed antibody boosts immune response against blood cancers and solid cancers

ASH 2025: Pirtobrutinib outperforms bendamustine plus rituximab for previously untreated CLL/SLL

ASH 2025: Tec-Dara combination offers substantial improvement over standard second-line therapies for relapsed or refractory multiple myeloma

ASH 2025: Chemo and radiation are comparable as pre-transplant conditioning for B-acute lymphoblastic leukaemia with no measurable residual disease

ASH 2025: Azacitidine–venetoclax combination outperforms standard care in acute myeloid leukaemia patients eligible for intensive chemotherapy

ASH 2025: Researchers identify CD40 as potential biomarker for a type of nodal T cell lymphoma

ASH 2025: Delayed toxicities after CAR T cell therapy for multiple myeloma are connected and potentially preventable

ASH 2025: Milder chemo works for rare, aggressive lymphoma

ASH 2025: Measurable residual disease shows strong potential as an early indicator of survival in acute myeloid leukaemia

ASH 2025: Continuous and fixed-duration treatments result in similar outcomes for CLL

Rituximab-based chemotherapy achieves strong outcomes without routine radiotherapy in stage I extranodal large B-cell lymphoma

Epcoritamab plus rituximab and lenalidomide improves efficacy in relapsed or refractory follicular lymphoma

Climate and environmental factors drive seasonal risk of invasive mucormycosis in haematologic malignancies

Extreme heat exposure around diagnosis is linked to higher mortality in multiple myeloma

Mismatching of unrelated donors beyond a single HLA-locus does not adversely impact outcomes following transplantation

Liso-cel in r/r follicular lymphoma shows durable 3-year responses and favourable long-term safety

TKI chemotherapy and ponatinib improve survival outcomes in blast phase CML

Consolidation treatment delays do not compromise survival in MRD-negative adult ALL

Non-TBI conditioning achieves positive results in MRD-negative CAYA B-ALL undergoing allogeneic HCT

Dasatinib, prednisone, and blinatumomab combination shows promising outcomes in elderly patients with Ph+ ALL

Blinatumomab plus chemotherapy shows manageable toxicity in adults with Ph- B-ALL

Pirtobrutinib significantly improves PFS in treatment-naïve CLL/SLL compared to bendamustine plus rituximab

Comment: Pirtobrutinib improves PFS in treatment-naïve CLL/SLL compared to bendamustine/rituximab

Glofitamab, venetoclax, and lenalidomide combination shows promising efficacy in high-risk mantle cell lymphoma

ASH 2025: Highlights

Ropeginterferon alfa-2b is evaluated as a disease-modifying option in essential thrombocythemia

Longer follow-up shows promising PFS + MRD negativity for mosunetuzumab use in untreated high tumour burden follicular lymphoma

Rusfertide provides durable control of haematocrit and phlebotomy reduction in polycythemia vera

Fixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLL

COVID-19 IgG antibodies induce endothelial activation, barrier dysfunction, and a prothrombotic state

Off-the-shelf in vivo CAR-T therapy KLN-1010 shows early MRD-negative responses in relapsed/refractory multiple myeloma

MRD validated as a surrogate endpoint for survival in AML

Zamtocabtagene autoleucel improves event-free survival vs standard of care in second-line r/r LBCL

Complement-bound procoagulant platelets predict thrombosis in antiphospholipid syndrome

Anitocabtagene autoleucel achieves deep and durable responses in relapsed/refractory multiple myelomas

IP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor-associated thrombosis

Exploring genomic insights in acute lymphoblastic leukaemia treatment

Talquetamab plus teclistamab shows promise in true extramedullary multiple myeloma

New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights blinatumomab benefits in key high-risk molecular types

Tec-Dara significantly improves PFS and OS compared to SoC in relapsed/refractory multiple myeloma

Black patients show inferior survival despite similar cytogenetics and treatment response

Asciminib shows high molecular response, favourable safety in 2L CML-CP

Rocbrutinib shows strong responses in resistant CLL, including BTKi- and venetoclax-exposed patients

Non-covalent BTK inhibitor pirtobrutinib shows promise as frontline therapy for CLL/SLL

Linvoseltamab monotherapy in newly diagnosed multiple myeloma shows impressive frontline responses